Phenotype | EUR | Non-EUR |
---|
N
| Affected patients, n (%) |
N
| Affected patients, n (%) | ORa (95% CI) | P valueb |
---|
Renal | 320 | 75 (24.4%) | 243 | 81 (33.3%) | 1.60 (1.11–2.32) | 0.01 |
Neurological | 330 | 36 (10.9%) | 244 | 42 (17.2%) | 1.67 (1.05–2.74) | 0.03 |
Haematological | 366 | 185 (50.5%) | 268 | 106 (39.6%) | 0.65 (0.47–0.89) | 0.007 |
dsDNA positivity | 370 | 143 (38.6%) | 270 | 83 (30.7%) | 0.70 (0.51–0.98) | 0.04 |
Admission ratec | 351 | 140 (39.9%) | 196 | 86 (43.9) | 1.20 (0.84–1.71) | 0.31 |
Biologics ever neededd | 332 | 23 (6.9%) | 239 | 12 (5.0%) | 0.70 (0.34–1.43) | 0.33 |
- Summary of available clinical history for the 656 study participants from cohort 3 since their disease diagnosis and up to the time of their visit. Data were stratified by study cohort
- CI confidence interval, EUR patients of European ancestry, non-EUR patients of non-European ancestry, SLE systemic lupus erythematosus
- aOdds ratio (OR) in non-European patients
- bP values calculated using Pearson’s chi-squared test
- cAdmission defined as any patient requiring hospital admission specifically for SLE in the 5 years prior to and including the date of their clinic visit at which the blood sample was taken
- dPatients treated with biologic drugs at any time since their disease diagnosis